Pfizer Acquires Metsera to Strengthen Obesity Treatment Portfolio
Pfizer has acquired biotech company Metsera for $4.9 billion to enhance its portfolio of long-lasting GLP-1 receptor agonists for weight loss, aiming to compete in the growing obesity treatment market, with the deal including milestone-based payments and a focus on monthly dosing therapies.